Phio Pharmaceuticals Corp Stock Investor Sentiment

PHIO Stock  USD 0.69  0.02  2.82%   
About 56% of all Phio Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Phio Pharmaceuticals Corp suggests that some traders are interested. Phio Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Phio Pharmaceuticals Corp. Many technical investors use Phio Pharmaceuticals Corp stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

Phio Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Phio Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
few days ago at finance.yahoo.com         
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
Yahoo News
over a week ago at benzinga.com         
Phio Pharmaceuticals And 2 Other Stocks Under 2 Insiders Are Buying
benzinga news
over a week ago at investing.com         
Phio Pharmaceuticals CEO buys 740 in company stock
Investing News at Macroaxis
over a week ago at investing.com         
Phio pharmaceuticals CEO buys 750 worth of company stock
Investing News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Robert Bitterman of 1000 shares of Phio Pharmaceuticals at 0.74 subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Acquisition by Robert Bitterman of 1000 shares of Phio Pharmaceuticals at 0.75 subject to Rule 16b-3
Macroaxis News
over three weeks ago at finance.yahoo.com         
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b ...
Yahoo News
over three weeks ago at investing.com         
Phio Pharmaceuticals advances to next dose in cancer trial
Investing News at Macroaxis
over three weeks ago at finance.yahoo.com         
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinica...
Yahoo News
over a month ago at seekingalpha.com         
Phio Pharmaceuticals files for 100M mixed shelf
seekingalpha News
over a month ago at globenewswire.com         
Phio Pharmaceuticals Secures New Investor
Macroaxis News: globenewswire.com
over a month ago at seekingalpha.com         
Phio Pharmaceuticals files for 100M mixed securities shelf
seekingalpha News
over a month ago at investing.com         
Phio Pharmaceuticals secures investment from TRITON Funds
Investing News at Macroaxis
over a month ago at finance.yahoo.com         
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology
Yahoo News
over a month ago at globenewswire.com         
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Phio Pharmaceuticals that are available to investors today. That information is available publicly through Phio media outlets and privately through word of mouth or via Phio internal channels. However, regardless of the origin, that massive amount of Phio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Phio Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Phio Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Phio Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Phio Pharmaceuticals alpha.

Phio Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Robert Bitterman of 300000 shares of Phio Pharmaceuticals at 0.1 subject to Rule 16b-3
04/01/2024
2
National Spotlight Features Phios Innovative RNAi Technology Platform
04/03/2024
3
Acquisition by Robert Bitterman of 2000 shares of Phio Pharmaceuticals at 0. subject to Rule 16b-3
04/19/2024
4
Intratumoral Injection of Phios PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
04/22/2024
5
Why Hibbett Shares Are Trading Higher By 18 Here Are 20 Stocks Moving Premarket
04/23/2024
6
Acquisition by Robert Bitterman of 40000 shares of Phio Pharmaceuticals subject to Rule 16b-3
04/26/2024
7
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology
04/30/2024
8
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
05/09/2024
9
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology
05/16/2024
10
Phio Pharmaceuticals Secures New Investor
05/17/2024
11
Phio Pharmaceuticals files for 100M mixed shelf
05/20/2024
12
Phio Pharmaceuticals advances to next dose in cancer trial
05/28/2024
13
Acquisition by Robert Bitterman of 1000 shares of Phio Pharmaceuticals at 0.75 subject to Rule 16b-3
06/06/2024
14
Acquisition by Robert Bitterman of 1000 shares of Phio Pharmaceuticals at 0.74 subject to Rule 16b-3
06/07/2024
15
Phio pharmaceuticals CEO buys 750 worth of company stock
06/10/2024
16
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
06/18/2024

Additional Information and Resources on Investing in Phio Stock

When determining whether Phio Pharmaceuticals Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phio Pharmaceuticals Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phio Pharmaceuticals Corp Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.52)
Return On Assets
(0.70)
Return On Equity
(1.45)
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.